Barclays PLC Fulcrum Therapeutics, Inc. Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 122,070 shares of FULC stock, worth $452,879. This represents 0.0% of its overall portfolio holdings.
Number of Shares
122,070
Previous 124,141
1.67%
Holding current value
$452,879
Previous $443,000
29.8%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding FULC
# of Institutions
142Shares Held
48.8MCall Options Held
6.8MPut Options Held
1.73M-
Ra Capital Management, L.P. Boston, MA10.2MShares$37.9 Million0.51% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$19.5 Million2.43% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$17.8 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.78MShares$17.7 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.25MShares$12.1 Million0.0% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $193M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...